Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients

Cancer Letters

Volumn 377, Issue 1, 2016, Pages 65-73

  Yin, Ji Ye ^a,b,c   Li, Xi ^a,b,c   Li, Xiang Ping ^a,b   Xiao, Ling ^a,b   Zheng, Wei ^a,b   Chen, Juan ^a,b   Mao, Chen Xue ^a,b   Fang, Chao ^a,b   Cui, Jia Jia ^a,b   Guo, Cheng Xian ^b   Zhang, Wei ^a,b,c   Gao, Yang ^a   Zhang, Chun Fang ^a   Chen, Zi Hua ^a   Zhou, Hui ^b   Zhou, Hong Hao ^a,b,c   Liu, Zhao Qian ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study   (China)

Author keywords

Data mining; NSCLC; Platinum; Response; SNP; Toxicity

Indexed keywords

PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE; TUMOR MARKER;

ACCURACY; ADULT; ADVANCED CANCER; ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; AGED; AREA UNDER THE CURVE; BAYES THEOREM; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DATA MINING; DECISION SUPPORT SYSTEM; GASTROINTESTINAL DISEASE; GENETIC PREDISPOSITION; GENETICS; HEMATOLOGIC DISEASE; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME; VALIDATION STUDY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BAYES THEOREM; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; DATA MINING; DECISION SUPPORT TECHNIQUES; FEMALE; GASTROINTESTINAL DISEASES; GENETIC PREDISPOSITION TO DISEASE; HEMATOLOGIC DISEASES; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PHENOTYPE; PLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TREATMENT OUTCOME;

EID: 84964499376     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.04.029     Document Type: Article

References (24)

1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin 2015, 65(2):87-108.
2. Hildebrandt M.A., Gu J., Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin. Drug Metab. Toxicol 2009, 5(7):745-755.
3. Giovannetti E., Toffalorio F., De Pas T., Peters G.J. Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?. Pharmacogenomics 2012, 13(9):1073-1086.
4. Yin J.Y., Huang Q., Zhao Y.C., Zhou H.H., Liu Z.Q. Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients. PLoS ONE 2012, 7(6). e38150.
5. Chen J., Yin J.Y., Li X.P., Wang Y., Zheng Y., Qian C.Y., et al. Association of Wnt-Inducible signaling pathway protein 1 genetic polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response. Clin. Lung Cancer 2015, 16(4):298-304. e1-2.
6. Yin J.Y., Meng X.G., Qian C.Y., Li X.P., Chen J., Zheng Y., et al. Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients. Acta Pharmacol. Sin 2015, 36(3):375-384.
7. Chen J., Yin J., Li X., Wang Y., Zheng Y., Qian C., et al. WISP1 polymorphisms contribute to platinum-based chemotherapy toxicity in lung cancer patients. Int. J. Mol. Sci 2014, 15(11):21011-21027.
8. Li X.P., Yin J.Y., Wang Y., He H., Li X., Gong W.J., et al. The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients. Tumor Biol 2014, 35(8):8259-8265.
9. Wang Y., Li X.P., Yin J.Y., Zhang Y., He H., Qian C.Y., et al. Association of HMGB1 and HMGB2 genetic polymorphisms with lung cancer chemotherapy response. Clin. Exp. Pharmacol. Physiol 2014, 41(6):408-415.
10. Wang Y., Yin J.Y., Li X.P., Chen J., Qian C.Y., Zheng Y., et al. The association of transporter genes polymorphisms and lung cancer chemotherapy response. PLoS ONE 2014, 9(3). e91967.
11. Xu X., Han L., Duan L., Zhao Y., Yang H., Zhou B., et al. Association between eIF3alpha polymorphism and severe toxicity caused by platinum-based chemotherapy in non-small cell lung cancer patients. Br. J. Clin. Pharmacol 2013, 75(2):516-523.
12. Ma'ayan A., Rouillard A.D., Clark N.R., Wang Z., Duan Q., Kou Y. Lean Big Data integration in systems biology and systems pharmacology. Trends Pharmacol. Sci 2014, 35(9):450-460.
13. Han J., Kamber M., Pei J.P.D. Data Mining: Concepts and Techniques 2012, Morgan Kaufmann, Waltham, MA, [Oxford: Elsevier Science, distributor].
14. Marateb H.R., Mansourian M., Adibi P., Farina D. Manipulating measurement scales in medical statistical analysis and data mining: a review of methodologies. J. Res. Med. Sci 2014, 19(1):47-56.
15. Sabbagh A., Darlu P. Data-mining methods as useful tools for predicting individual drug response: application to CYP2D6 data. Hum. Hered 2006, 62(3):119-134.
16. Li X., Liu R., Yan H., Tang J., Yin J.Y., Mao X.Y., et al. Effect of CYP2C9-VKORC1 interaction on warfarin stable dosage and its predictive algorithm. J. Clin. Pharmacol 2015, 55(3):251-257.
17. Li X., Liu R., Luo Z.Y., Yan H., Huang W.H., Yin J.Y., et al. Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algorithms using seven mathematical models in Chinese patients. Pharmacogenomics 2015, 16(6):583-590.
18. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst 2000, 92(3):205-216.
19. Galluzzi L., Vitale I., Michels J., Brenner C., Szabadkai G., Harel-Bellan A., et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 2014, 5:e1257.
20. Hall M., Frank E., Holmes G., Pfahringer B., Reutemann P., Witten I.H. The WEKA data mining software: an update. SIGKDD Explor 2009, 11(1):1-18.
21. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21(2):263-265.
22. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet 2007, 81(3):559-575.
23. McWhinney S.R., Goldberg R.M., McLeod H.L. Platinum neurotoxicity pharmacogenetics. Mol. Cancer Ther 2009, 8(1):10-16.
24. Shen D.W., Pouliot L.M., Hall M.D., Gottesman M.M. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev 2012, 64(3):706-721.